Antibody Drug Conjugates [ADC] Market Size to Surpass US$ 24.70 Billion by 2032, Driven by…

The rapid evolution of Antibody Drug Conjugates and their adoption in cancer treatment, particularly in addressing previously challenging cancer types. Technological advancements and successful clinical trials are boosting the market, positioning ADCs as a key element in the future of oncology.